Picking up on the ICH implementation, I think we need to state very categorically and strongly that there is no intention in the modernization to decrease the amount of science that you need to get approved to make sure that there is a favourable benefit and risk for the product when it goes onto the market. That's very important to state. So there is no compromise or shortening on that at all.
The idea is that as you go from the pre-market, which is really an experimenting with the drug, there are still quite a few things you don't know when it gets out into the real population. That's where the science is really starting to grow. It is fairly new. We probably don't have enough pharmacoepidemiologists in the country.
There is a lot of hope, though, that we can work with our decision-making partners in the provinces and so on to really get the best interventions when they make sense. So you really want to keep your surveillance of those risks that are plausible risks that make sense.
And there is a lot of planning element now, so pre-market, a lot of what's in the international environment is making sure that before a drug company is allowed to sell a drug, even in the pre-market situation, they have a really good plan for how they're going to track risks out on the market. And there is a lot more commitment to that planning.
And that starts to appear in regulations. That's not about decreasing the standard for getting on; it's really about governing, and looking, and planning well. Planning doesn't get you everything, so you still need interventions if something is going wrong with a drug, but the idea of planning is fundamentally a good one, we think, and it will improve the oversight.